Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17280354 | 0.91 | KDM4E (0.46) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL15920683 | 0.90 | KDM4E (0.58) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280374 | 0.89 | KDM4E (0.47) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280365 | 0.89 | ALDH1A1 (0.49) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280366 | 0.88 | KDM4E (0.44) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280371 | 0.87 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280353 | 0.85 | MAPT (0.57) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280357 | 0.85 | KDM4E (0.65) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280380 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL17280378 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1MAPTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650355-B2 | Method for preparation of justicidin a derivatives of arylnaphthalene lignan structure | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-05-16 | — | — | US | disclosed |
| US-20150336938-A1 | METHOD FOR PREPARATION OF JUSTICIDIN A DERIVATIVES OF ARYLNAPHTHALENE LIGNAN STRUCTURE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336938-A1 | METHOD FOR PREPARATION OF JUSTICIDIN A DERIVATIVES OF ARYLNAPHTHALENE LIGNAN STRUCTURE | UGT1A8, NOTUM, MLN | KDM4E 3104/4885ALDH1A1 241/4885MAPT 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.